Beam Therapeutics (BEAM) Change in Account Payables (2019 - 2026)

Beam Therapeutics (BEAM) has reported Change in Account Payables for 8 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables fell 41.58% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $4.5 million (up 3.43% YoY), while the FY2025 annual figure was $6.0 million, up 234.26% from the prior year.
• Change in Account Payables improved to $2.2 million in Q1 2026 per BEAM's latest filing, from $1.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $3.8 million in Q1 2025 and bottomed at -$3.0 million in Q3 2023.
• Historically, Change in Account Payables has averaged $285764.7 across 5 years, with a median of $102000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Account Payables sank 2584.31% — and 2024, when it jumped 656.28%.
• Beam Therapeutics' Change in Account Payables stood at $2.9 million in 2022, then tumbled by 160.97% to -$1.8 million in 2023, then soared by 68.89% to -$550000.0 in 2024, then soared by 317.09% to $1.2 million in 2025, then surged by 85.59% to $2.2 million in 2026.
• Business Quant data shows BEAM's Change in Account Payables at $2.2 million in Q1 2026, $1.2 million in Q4 2025, and -$1.6 million in Q3 2025.